Sirolimus conversion in liver transplant recipients with renal dysfunction: A prospective, randomized, single-center trial

Transplantation

Volumn 83, Issue 10, 2007, Pages 1389-1392

  Shenoy, Surendra ^a,c   Hardinger, Karen L ^b   Crippin, Jeffrey ^a   Desai, Niraj ^a   Korenblat, Kevin ^a   Lisker Melman, Mauricio ^a   Lowell, Jeffrey A ^a   Chapman, William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

Liver transplantation; Renal toxicity; Sirolimus

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTEREMIA; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEMATOCRIT; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; INFECTION COMPLICATION; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MEDICAL ASSESSMENT; MONOTHERAPY; MOUTH PAIN; NEPHROTOXICITY; PATIENT MONITORING; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR GROWTH;

AGED; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS, LDL; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; SIROLIMUS; TRIGLYCERIDES;

EID: 34249012330     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000261630.63550.41     Document Type: Article

References (26)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
2. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72: 1934.
3. Grinyo JM. Progress with cyclosporine sparing regimens. Trans Proc 1999; 31(Suppl 8A): 11S.
4. Sabbatini M, Sansone G, Uccello F, et al. Acute effects of rapamycin on glomerular dynamics: A micropuncture study in the rat. Transplantation 2000; 69: 1946.
5. Encke J, Uhl W, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. Nephrol Dial Transplant 2004; 19(Suppl 4): iv22.
6. Schmeding M, Neumann UP, Neuhaus R, Neuhaus P. Mycophenolate mofetil in liver transplantation - is monotherapy safe? Clin Transplant 2006; 20(Suppl 17): 75.
7. Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long term and short term cyclosporine followed by azathioprine and prednisone and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499.
8. Groth CG, Backman L, Morales JM, et al. Sirolimus based therapy in human renal transplantation. Sirolimus European Renal Transplant Study Group. Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036.
9. Macdonald AS. Management strategies for nephrotoxicity. Transplantation 2000; 69: SS31.
10. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079.
11. Cotterell AH, Fisher RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16: 49.
12. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126.
13. Hocker B, Feneberg R, Kopf S, et al. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006; 10: 593.
14. Maheshwari A, Torbenson MS, Thuluvath PJ. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci 2006; 51: 1677.
15. Backman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattstrom C. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus. Clin Transplant 2006; 20: 336.
16. Sanchez EQ, Martin AP, Ikegami T, et al. Sirolimus conversion after liver transplantation: Improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005; 37: 4416.
17. Montalbano M, Neff GW, Slapak-Green G, Berney T, Meyer D. Sirolimus therapy in orthotopic liver transplant (OLT) recipients with acute renal insufficiency. Dig Dis Sci 2004; 49: 1986.
18. Lam P, Yoshida A, Brown K, et al. The efficacy and limitations of sirolimus conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 2004; 49: 1029.
19. Product Information: Rapamune® (sirolimus) Oral Solution and Tablets. Philadelphia: Wyeth Laboratories, Division of Wyeth-Ayerst Pharmaceuticals Inc.; 2006.
20. Calne RY, Thiru S, McMaster P, Craddock GN, White DJ, Evans DJ, Dunn DC, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. 1978. J Am Soc Nephrol 1998; 9: 1751.
21. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333.
22. Vivarelli M, Vetrone G, Zanello M, et al. Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: A report of six. Transpl Int 2006; 19: 1022.
23. Rogers C, Johnson S, Snow E, et al. Early sirolimus conversion is superior to late sirolimus conversion n reversing renal dysfunction in liver transplant recipients (abstract 493).AmJ Transplant 2006; 5(Suppl 11): 571.
24. Dittrich E, Schmaldienst S, Soleiman A, HorlWH, Pohanka E. Rapamycinassociated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 2004; 17: 215.
25. Bumbea V, Kamar N, Ribes D, Esposito L, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517.
26. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 2088.